#Scientificpaper: The scientific journal Protein Expression and Purification published our findings using the innovative STEP® vector technology. It's the ideal solution for #difficulttoexpress #proteins. Congratulations to the author and co-authors! bataviabiosciences.com/media/step-cho…

We're proud to announce our collaboration with RocketVax, a subsidiary of Swiss Rockets. Batavia will develop the clinical process and deliver clinical product of RocketVax’s highly promising second generation SARS-CoV-2 vaccine candidate. #covid19vaccine #bioprocessing #CDMO

We have successfully manufactured clinical trial material using HIP-Vax! We produced IAVI's #Lassavaccine candidate for Phase I. HIP-Vax uses the novel fixed-bed bioreactor, scale-X. This is the first clinical batch ever produced on a scale-X system. bataviabiosciences.com/news/hip-vax-l…

Developing a #vectorvaccine or #virotherapy? Here is our extensive guide to #viralvector process development and scale-up. Learn how to get from bench to clinic faster. blog.bataviabiosciences.com/guide-to-viral… #GeneTherapy #oncolyticvector #bioprocessing #CDMO #cGMP #processdevelopment

#Scientificpublication: Human Vaccines & Immunotherapeutics has published scientific data generated together with University of Kansas on #formulationdevelopment of a live-attenuated, neonatal #rotavirus vaccine candidate (RV3-BB). Congratulations to all authors! bataviabiosciences.com/media/scientif…

Through an innovative partnership model among IAVI, CEPI, & an expert consortium of collaborators, we plan to further support the development of IAVI’s Lassa fever vaccine candidate with our HIP-Vax platform. #bioprocessing #CDMO #vectorvaccines

Would you like to work on cutting-edge therapies which will shape the future? Batavia is expansing its process development capacity for viral vectors in the Boston area. bataviabiosciences.com/news/expanding… #lifesciencejobs #vacancies #viralvectors #bioprocessing #CDMO #companygrowth

#ScientificPublication: We are proud to announce that the peer-reviewed journal Biologicals has now published our work on the stable high yield expression of an HIV envelope protein using our STEP technology. #proteinexpression #CDMO bataviabiosciences.com/media/stable-h…

How do #biotech #startups find their niche in the funding ecosystem? What are the factors for success? Learn all about it in our new blog! bataviabiosciences.com/media/biotech-… #venturecapital #funding #success #entrepreneurship #centerofexcellence #bioprocessing

A well-crafted product development plan (#PDP) can play a pivotal role in the development and commercialization of a new drug product. Learn how to kick-start your #drugdevelopment strategy. bataviabiosciences.com/media/drug-dev… #riskmitigation #bioprocessing #CMC #strategy #CDMO

We wish you and your loved ones a safe, and joyous #holidayseason. While this year has had its challenges, it also highlighted what is truly important: #wellbeing, #lovedones and the precious time spent together. Let’s strive to bring smiles on people’s faces in 2022.

Introducing the new #LEAP4WA website – a one stop shop where you can learn about this innovative, international collaboration that is advancing an effective vaccine to prevent #Lassafever in West Africa.🌍 🔗Learn more at LEAP4WA.org

We’re joining NIIMBL! As a member, we continue to work towards accelerating biopharmaceutical innovation, facilitating development of industry standards, and supporting access to a world leading biopharmaceutical workforce. #bioprocessing #CDMO bataviabiosciences.com/batavia-joins-…

#Adenovirus vectors have an impressive track record and are used in some of the most high-profile clinical trials in the field of #genetherapy, and have been approved as vaccine carriers to battle COVID-19. Check out the 1st of our 3-part series here! bataviabiosciences.com/past-and-curre…

We can't wait for the year's premier vaccine event, World Vaccine Congress, where our own Director of Operations will be offering his insight into adenovirus vectored vaccines. Come discuss opportunities to bring your vaccine candidate from bench to clinic! #WVCDC bataviabiosciences.com/world-vaccine-…

Today, Batavia Biosciences announces the expansion of its headquarters and R&D capacities by another 22,500 sq. ft. This expansion will aid in our journey to meet increased global demand for vaccine development and virotherapies. Read more about it here! bataviabiosciences.com/batavia-biosci…

In a MAJOR development, Batavia Biosciences is proud to announce that we will be entering the commercial manufacturing business. We will be opening a state-of-the-art, 12,000 square meter facility in Leiden, The Netherlands. bataviabiosciences.com/batavia-enters… #Bioprocessing #globalhealth

PRESS RELEASE: Batavia announces that we’ve teamed up with Veeva to further optimize our global quality assurance with Veeva Vault Quality Suite. Batavia will benefit by unifying content, processes, and training management all on a single platform. bataviabiosciences.com/batavia-biosci…

Good news for #vaccines in #africa as Institut Pasteur de Dakar works with Univercells and Batavia Biosciences with support from Gates Foundation against #measles and #rubella. #vaccinenation #senegal #vaccines #vaccine #afrique vaccinenation.org/global-health/…